News3SBio Selects Verseau’s PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration November 18, 2019Verseau Therapeutics Appoints Tim Smith as Chief Business Officer November 13, 2019Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board October 21, 20193SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies February 11, 2019
